Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

Phase 2

Completed

Conditions: Hemorrhagic Stroke
Intracerebral Hemorrhage (ICH)

Interventions: Drug: BAF312 solution
Drug: Matching Placebo for BAF312 solution
Drug: Matching Placebo for BAF312 tablet
Drug: BAF312 tablet

First Posted Date: 2017-11-09

Last Posted Date: 2022-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT03338998

Locations: 🇺🇸
Novartis Investigative Site, Charlottesville, Virginia, United States

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Phase 1

Terminated

Conditions: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Interventions: Drug: Placebo Cutaneous Cream application
Drug: Cutaneous Cream application

First Posted Date: 2017-11-07

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03333694

Locations: 🇧🇪
Novartis Investigative Site, Liege, Belgium

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: KAE609
Drug: Coartem

First Posted Date: 2017-11-07

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 188

Registration Number: NCT03334747

Locations: 🇺🇬
Novartis Investigative Site, Tororo, Uganda

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

Phase 2

Terminated

Conditions: Knee Cartilage Lesion

Interventions: Biological: LNA043
Biological: placebo to LNA043

First Posted Date: 2017-11-07

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03334812

Locations: 🇦🇹
Novartis Investigative Site, Wien, Austria

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1

Active, not recruiting

Conditions: EGFR-mutant Non-small Cell Lung Cancer

Interventions: Drug: EGF816
Drug: LXH254
Drug: trametinib
Drug: ribociclib
Drug: gefitinib
Drug: INC280

First Posted Date: 2017-11-06

Last Posted Date: 2024-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03333343

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Biological: Erenumab
Other: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT03333109

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Omalizumab
Drug: Placebo

First Posted Date: 2017-11-01

Last Posted Date: 2020-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT03328897

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: LIK066
Drug: Placebo

First Posted Date: 2017-10-25

Last Posted Date: 2024-06-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT03320941

Locations: 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Everolimus Placebo

First Posted Date: 2017-10-18

Last Posted Date: 2024-01-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 159

Registration Number: NCT03312738

Locations: 🇨🇳
Novartis Investigative Site, Wuhan, China

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: LHC165
Biological: PDR001

First Posted Date: 2017-10-04

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03301896

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy